Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland

Major Program
Cancer Prevention Clinical Trials Network
Research Group
Prostate and Urologic Cancer
National Cancer Institute (NCI)
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT04530552
This phase IIa trial investigates the biomarker (plasma levels of PSA) of low-dose
apalutamide in patients with prostate cancer confined in the prostate gland before surgery.
Testosterone can cause the growth of prostate cancer cells, and Apalutamide blocks the use of
testosterone by the tumor cells. Giving low-dose apalutamide before prostate surgery may lead
to lowered PSA levels in men with prostate cancer confined to the prostate gland.
Apalutamide, Quality-of-Life Assessment, Biospecimen Collection
Localized Prostate Carcinoma, Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8
Juan Chipollini, Hsiao-Hui (Sherry) Chow, Mike M. Nguyen, John K. Parsons, Christian P. Pavlovich, Peter A. Pinto, Michael J. Whalen

See list of participating sites